Re-exposure to mismatched HLA class I is a significant risk factor for graft loss: Multivariable analysis of 259 kidney retransplants

Transplantation

Volumn 84, Issue 6, 2007, Pages 722-728

  House, Andrew A ^a,b   Chang, Peter C W ^a   Luke, Patrick P ^a   Leckie, Stephen H ^a   Howson, William T ^a   Ball, Edward J ^a   Tan, Ann K L ^a   Rehman, Faisal ^a   Muirhead, Norman ^a   Hollomby, David J ^a   McAlister, Vivian C ^a   Hodsman, Anthony B ^a   Jevnikar, Anthony M ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b LONDON HEALTH SCIENCES CENTRE   (Canada)

Author keywords

Graft survival; Histocompatibility testing; HLA antigens; Kidney transplantation; Multivariate analysis; Reoperation

Indexed keywords

LEUKOCYTE ANTIGEN;

ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FOLLOW UP; GRAFT FAILURE; GRAFT SURVIVAL; HISTOCOMPATIBILITY TEST; HLA SYSTEM; HUMAN; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; REOPERATION; RISK FACTOR;

FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HISTOCOMPATIBILITY; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA-A ANTIGENS; HLA-B ANTIGENS; HUMANS; KIDNEY TRANSPLANTATION; MALE; REOPERATION; RISK;

EID: 34748853695     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000281398.41670.1f     Document Type: Article

References (36)

1. Opelz G. Repeated HLA mismatches increase the failure rate of second kidney transplants. Transplant Proc 1995; 27: 658.
2. Cecka JM, Terasaki PI. Repeating HLA antigen mismatches in renal retransplants - a second class mistake? Transplantation 1994; 57: 515.
3. Farney AC, Matas AJ, Noreen HJ, et al. Does re-exposure to mismatched HLA antigens decrease renal retransplant allograft survival. Clin Transplant 1996; 10: 147.
4. Tufveson G, Bengtsson M, Bergstrom C, et al. Is repeated mismatching at regrafting deleterious. Transpl Int 1992; 5: S140.
5. Mjornstedt L, Konar J, Nyberg G, et al. Renal retransplantation in patients with HLA-antibodies. Transpl Int 1992; 5: S32.
6. Gjertson DW. A multi-factor analysis of kidney regraft outcomes. Clin Transpl 2002; 335.
7. Terasaki PI, Bernoco D, Park MS, et al. Microdroplet testing for HLA-A, -B, -C and D antigens. Am J Clin Pathol 1978; 69: 103.
8. Olerup O, Zetterquist H. HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours: An alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantations. Tissue Antigens 1992; 39: 225.
9. Bunce M, O'Neill CM, Barnardo MC, et al. Phototyping: comprehensive DNA typing for HLA-A, B C, DRB1, DRB3, DRB4, DRB5 & DQB1 by PCR with 144 primer mixes utilizing sequence-specific primers (PCR-SSP). Tiss Antigens 1995; 46: 355.
10. Bidwell JL, Bidwell EA, Savage DA, et al. A DNA-RFLP typing system that positively identifies serologically well-defined and ill-defined HLA-DR and DQ alleles, including DRw10. Transplantation 1988; 45: 640.
11. Uryu N, Maeda M, Ota K, et al. A simple and rapid method for HLADRB and-DQB typing by digestion of PCR-amplified DNA with allele specific restriction endonucleases. Tissue Antigens 1990; 35: 20.
12. Ting A. The lymphocytotoxic crossmatch test in clinical renal transplantation. Transplantation 1983; 35: 403.
13. Ayoub G, Park MS, Terasaki PI, et al. B cell antibodies and cross-matching. Transplantation 1980; 29: 227.
14. Johnson AH, Rossen RD, Butler WT. Detection of alloantibodies using a sensitive antiglobulin microcytotoxicity test: Identification of low levels of pre-formed antibodies in accelerated allograft rejection. Tissue Antigens 1972; 2: 215.
15. Steen SI, Cheng CY, Ting A, et al. Simplification of the antiglobulin-augmented lymphocytotoxicity test: addition of the AHG to the complement [abstract]. Hum Immunol 1994; 40: 136.
16. van Kampen CA, Roelen DL, Versteeg-van der Voort Maarschalk MF, et al. Activated HLA class I-reactive cytotoxic T lymphocytes associated with a positive historical crossmatch predict early graft failure. Transplantation 2002; 74: 1114.
17. Karpinski M, Rush D, Jeffery J, et al. Flow cytometric crossmatching in primary renal transplant recipients with a negative anti-human globulin enhanced cytotoxicity crossmatch. J Am Soc Nephrol 2001; 12: 2807.
18. Süsal C, Opelz G. Kidney graft failure and presensitization against HLA class I and class II antigens. Transplantation 2002; 73: 1269.
19. Ettinger RB, Terasaki PI, Opelz G, et al. Successful renal allografts across a positive cross-match for donor B-lymphocyte alloantigens. Lancet 1976; 2: 56.
20. Bittencourt MC, Rebibou JM, Saint-Hillier Y, et al. Impaired renal graft survival after a positive B-cell flow-cytometry crossmatch. Nephrol Dial Transplant 1998; 13: 2059.
21. Mahoney RJ, Taranto S, Edwards E. B-cell crossmatching and kidney allograft outcome in 9031 United States transplant recipients. Hum Immunol 2002; 63: 324.
22. Gebel HM, Bray RA, Nickerson P. Pre-transplant assessment of donorreactive, HLA-specific antibodies in renal transplantation: contraindication vs risk. Am J Transplant 2003; 3: 1488.
23. Bearden CM, Agarwal A, Book BK, et al. Pronase treatment facilitates alloantibody flow cytometric and cytotoxic crossmatching in the presence of rituximab. Hum Immunol 2004; 65: 803.
24. Takemoto SK, Zeevi A, Feng S, et al. National conference to assess antibody-mediated rejection in solid organ transplantation. Am J Transplant 2004; 4: 1033.
25. Opelz G, Scherer S, Mytilineos J. Analysis of HLA-DR split-specificity matching in cadaver kidney transplantation. Transplantation 1997; 63: 57.
26. Opelz G. Importance of HLA antigen splits for kidney transplant matching. Lancet 1988; 2: 61.
27. Mytilineos J, Lempert M, Middleton D, et al. HLA class I DNA typing of 215 "HLA-A, -B, -DR zero mismatched" kidney transplants. Tissue Antigens 1997; 50: 355.
28. Opelz G, Wujciak T, Dohler B, et al. HLA compatibility and organ transplant survival. Collaborative Transplant Study. Rev Immunogenet 1999; 1: 334.
29. Mytilineos J, Deufel A, Opelz G. Clinical relevance of HLA-DPB locus matching for cadaver kidney retransplants: A report of the Collaborative Transplant Study. Transplantation 1997; 63: 1351.
30. Thompson JS, Thacker LR 2nd, Krishnan G. Human leukocyte antigens DR and AB and kidney retransplantation. Transplantation 2003; 75: 718.
31. Kieszak SM, Flanders WD, Kosinski AS, et al. A comparison of the Charlson comorbidity index derived from medical record data and administrative billing data. J Clin Epidemiol 1999; 52: 137.
32. Quan H, Parsons GA, Ghali WA. Validity of information on comorbidity derived from ICD-9-CCM administrative data. Med Care 2002; 40: 675.
33. Matas AJ, Gillingham KJ, Sutherland DE. Half-life and risk factors for kidney transplant outcome - importance of death with function. Transplantation 1993; 55: 757.
34. Koo DD, Roberts IS, Quiroga I, et al. C4d deposition in early renal allograft protocol biopsies. Transplantation 2004; 78: 398.
35. Mizutani K, Terasaki P, Hamdani E, et al. The importance of anti-HLA-specific antibody strength in monitoring kidney transplant patients. Am J Transplant 2007; 7: 1027.
36. Mao Q, Terasaki PI, Cai J, El-Awar N, Rebellato L. Analysis of HLA class I specific antibodies in patients with failed allografts. Transplantation 2007; 83: 54.